Boston Scientific Corp.

Boston Scientific, a Marlborough medical device manufacturer, has officially closed its acquisition of California medical device maker Silk Road Medical, almost exactly three months to the day since Boston Scientific signed its purchase agreement. 

Ernie Herrman, president and CEO of The TJX Cos. in Framingham, was the highest-paid CEO among Central Massachusetts public companies for fiscal 2023.

Marlborough medical device manufacturing firm Boston Scientific looks to soon add stroke prevention treatment to its portfolio, as the manufacturer has entered into a $1.16 billion agreement to purchase California-based medical device company Silk Road Medical.

Boston Scientific has added a new member to its board of directors, naming Dr. Cheryl Pegus as the board’s latest addition, effective immediately. 

The U.S. Food and Drug Administration has issued a recall of Boston Scientific’s Obsidio conformable embolic medical device after an investigation found using the product for lower gastrointestinal bleeding embolization can result in a high risk of bowel ischemia, otherwise known as reduced or restricted blood flow.

The primary use of the funds will be used to fund Boston Scientific’s purchase of Axonics, Inc., a $3.7-billion transaction the company announced in January. 

Marlborough medical technology firm Boston Scientific has received approval from the U.S. Food and Drug Administration for its WaveWriter Alpha spinal cord stimulator device to be used to treat low back and leg pain deriving from a condition referred to as non-surgical back pain. 

The situation in Central Massachusetts, where 15.6% of named executive officers are female, largely mirrors the Massachusetts rate of 16.1% determined in a statewide census.

Marlborough medical device manufacturer Boston Scientific has reached agreement to purchase Axonics Inc., a company based in California specializing in devices used to treat urinary and bowel dysfunction.

Marlborough medical technology firm Boston Scientific has initiated a new clinical trial to study a treatment of persistent atrial fibrillation, an irregular rapid heart rhythm.